t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5-Reference-Cited by-同舟云学术

t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5

Published:2013-01-23 Issue:1 Volume:8 Page:e53767
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ehrentraut Stefan,Nagel Stefan,Scherr Michaela E.,Schneider Björn,Quentmeier Hilmar,Geffers Robert,Kaufmann Maren,Meyer Corinna,Prochorec-Sobieszek Monika,Ketterling Rhett P.,Knudson Ryan A.,Feldman Andrew L.,Kadin Marshall E.,Drexler Hans G.,MacLeod Roderick A. F.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms;S Hoeller;Expert Opin Ther Targets,2011

2. Janus kinase deregulation in leukemia and lymphoma;E Chen;Immunity,2012

3. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression;S Radtke;J Biol Chem,2005

4. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin;MA Dawson;Nature,2009

5. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation;X Lu;Proc Natl Acad Sci U S A,2005

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia;Genes, Chromosomes and Cancer;2024-06

2. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma;Blood;2023-10-12

3. How molecular advances may improve the diagnosis and management of PTCL patients;Frontiers in Oncology;2023-06-23

4. Primary cutaneous gamma/delta T‐cell lymphoma with simultaneous JAK2 and TP63 rearrangements: a new double‐hit?;Histopathology;2023-06-12

5. Moving towards biologically informed treatment strategies for T-cell lymphomas;International Journal of Hematology;2022-12-27